ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. S
MarketBeat ·